Related references
Note: Only part of the references are listed.Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver J. Kennedy et al.
EUROPEAN JOURNAL OF CANCER (2022)
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2021)
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma
Jeffrey S. Weber et al.
EUROPEAN JOURNAL OF CANCER (2021)
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies
Sruthy Varghese et al.
MOLECULAR CANCER THERAPEUTICS (2021)
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen et al.
NATURE MEDICINE (2021)
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients
Diwakar Davar et al.
SCIENCE (2021)
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma
Walter J. Storkus et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Craig L. Slingluff et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Relevance of Vitamin D in Melanoma Development, Progression and Therapy
Anna A. Brozyna et al.
ANTICANCER RESEARCH (2020)
Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study
Sanne Huijberts et al.
FUTURE ONCOLOGY (2020)
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
Ruth Plummer et al.
BRITISH JOURNAL OF CANCER (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
John P. Fruehauf et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Tuba N. Gide et al.
CLINICAL CANCER RESEARCH (2018)
Overcoming resistance to BRAF inhibitors
Imanol Arozarena et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial
J. De Smedt et al.
BMC CANCER (2017)
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
J. Guo et al.
ANNALS OF ONCOLOGY (2017)
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Zeynep Eroglu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T)
Asad Javed et al.
FUTURE ONCOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)
David H. Lawson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma
Jason J. Luke et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
John F. Thompson et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V. Long et al.
NATURE COMMUNICATIONS (2014)
β-Blockers and Survival among Danish Patients with Malignant Melanoma: A Population-Based Cohort Study
Stanley Lemeshow et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Key Concepts of Clinical Trials: A Narrative Review
Craig A. Umscheid et al.
POSTGRADUATE MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine
D Berd et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastases
D Berd et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
